Crisis, the pharmaceutical industry has identified the target

Until the year 2012 total 300 million U.S. dollars export target is, but this target due to the crisis has been identified indicating Mustafa Nevzat Drug Industry General Manager Levent Selamoğlu, "the crisis would be that way to go we hope. But in 2012 he no longer went to 2015." he said.

Mustafa Nevzat Drug Industry General Manager Selamoğlu, affected by global economic crisis, the most common cause of major cost increases that were expressed. Turkey's pharmaceutical industry in general is similar to the pharmaceutical industry in the world to live in Turkey and a table of the imported drugs are a significant part hammaddesinin that point Selamoğlu, that the cost of imported inputs increased pressure on the exchange is made.

COST ART was not performed PRICE REGULATION
Within the past year, increasing electricity and natural gas fiyatlarınında themselves severely affected by Selamoğlu said, "Labor costs also has increased. All this we have put on top when the last quarter of the year in Turkey, especially in the pharmaceutical industry production in the company average of around 25-30 per cent cost The increase in cases was. This made the cost of medicines in Turkey by the government determined prices for the drugs did not increase at all in the posture. Therefore, at this time of the Turkish pharmaceutical industry, a serious increase in costs faced. But no price regulation have been made. It's long-term Turkish pharmaceutical industry will be seriously affected. hope that the government, the Ministry of Health and Ministry of Finance to take necessary measures related to the implementation of the current price regulation in Turkey will make an arrangement with the pharmaceutical price "as it had not.

Crisis of the world pharmaceutical industry what the impact assessed Levent Selamoğlu, "the world of the pharmaceutical companies as a serious cost has increased. This increase in cost, depending on who they are working on positioning. Özellikle use financing for the company a serious interest or pressure to find funding pressures have . All this, in general negative affect factors. But once there is a positive situation, in this crisis in drug demand is not narrowing. Ilac In this sense, immune to attack an industry. People get ill when you attack or not to take medication in case. In this sense, in other industries As no contraction in demand, "he said.

Mustafa Nevzat Pharmaceuticals in 2007's America started exporting a product that reminds Selamoğlu, in June 2008 in the second product into the market and now are waiting for a third of the product made out of license. 2009 in the third, fourth or maybe fifth of products into the U.S. market will be Selamoğlu expression, "the American market for the foreseeable a sales chart was fast, but slowly rising steadily ... O framework currently our exports continues. Hopefully, this crisis from the I look will not be affected. We did not see much of an impact it, "he said.

Company in 2008 as a live negativity, even in the last quarter started with the crisis, the negative impact felt more strongly started to tell Levent Selamoğlu, in 2008 the budget to keep the target was close, but from September 2008 since the 2009 budget to create söyledi. Selamoğlu, 2008 turnover of 180 million dollars was added to the word.

SOME INVESTMENTS Suspended
Increasing cost pressures, price increases and the establishment such as the uncertainty of the year 2009 for a numerical target is difficult to tell that Selamoğlu recording said: "(for 2009) 100 TL U.S. Our scenario also has 10 TL line our scenario and that a broad range look. 2009 than previously planned investment had, I currently have suspended. Plant additional production space to add our projects are in condition has stopped. Şekerpınar'da got a plant, it has been considered for a project had it suspended status are. 2009 about investment in the current conditions, only the essential, very urgent to do, things have limits. But conditions change, the economic environment in Turkey goes to the better if the existing projects will revive. 2009 in the United States than three of our products to enter into hope. but in addition to the 28 countries we We are exporting. this country is the number of 35'e are planning to remove. Current on it are working. Germany is very high in our exports there, there's enlargement bekliyoruz. England would enter the market in 2009 in. Yurt is a new year just two new products were launched on the market. Year until the end of the probably 8 to 10 around the product to market we'll think. 2009 in the circuit will enter into a new factory have; Investment in 2007 began, was completed in 2008. Current pilot production finished. ready for commercial production has become. Cancer products will produce a plant. In 2009 the cancer products will begin to sell in both Turkish and world markets. The 25 million dollar investment. "

YEAR 2012, went ARTIK 2015
Until the year 2012 total 300 million U.S. dollars export target is, but this target due to the crisis has been identified indicating Mustafa Nevzat Drug Industry General Manager Levent Selamoğlu, "the crisis would be that way to go we hope. But in 2012 he no longer went to 2015." he said.

Turkish pharmaceutical sector, especially the price nün serious about the expectation that indicates Selamoğlu, "for myself I would say, the Indian government or the government of Poland, Hungary's government, China's government on its own pharmaceutical industry is how you look at it, we of the Turkish government in the Turkish pharmaceutical industry, especially in Turkey production of the company so we want to look. look extremely careful that we know, but we have enough understanding and enough that we do not believe reviews. So the Turkish pharmaceutical industry production technology and capacity to host the human resources in Turkey today and how a large automotive exports has been the means of the same drug things may happen. So we not only spend money that occasion as an industry not to earn the money, countries can provide an input as an industry need to see the government. Görenler are absolutely, is our fault necessarily. So that we ourselves enough but expressed a view that the Turkish pharmaceutical industry, exporting to, R & D can do its own drug molecules discovered and developed in one direction may bring. " he said.

R & D to have SERIOUS INVESTMENT
In Turkey, R & D investment is not just the past year being the R & D Act, together with a serious future developments can be expressed as the Selamoğlu, "company as R & D means a serious investment we have. At the moment our staff close to 40 R & D from running. TÜBİTAK and universities are doing joint projects. In this sense, future studies are serious. " he said.

We are not against foreign partners to
Selamoğlu 100 percent of local companies to foreign partners by how they look is on the question, "Foreign partners are not against. Domestic partners also are not met. But the partnership, or business units to bring an added value should be. We will create added value, all business units are ready to . " gave the answer.
Levent also expressed think Selamoğlu public offerings, "indicates that we do not know what the future requirements, but current conditions is not already public offering, a method very attractive." he said.